RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Short Interest Down 82.9% in June

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 338 shares, a drop of 82.9% from the June 15th total of 1,978 shares. Based on an average daily volume of 503 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.0% of the shares of the stock are sold short.

RCN Pareto Strategic Allocation ETF Stock Down 1.3%

Shares of RCN Pareto Strategic Allocation ETF stock traded down $0.35 during trading hours on Monday, reaching $27.23. The company’s stock had a trading volume of 6 shares. RCN Pareto Strategic Allocation ETF has a one year low of $24.68 and a one year high of $28.16. The company has a market cap of $603.93 million, a PE ratio of -28.36 and a beta of 0.60.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.